Market Analysis - Monthly Report - September, 2020 - Fine Chemical
ECHEMI monthly report of fine chemical in September 2020
Looking at the market outlook, October is still the traditional peakseason, the market mentality is still optimistic, the downstream or thewillingness to replenish the stock after the festival, and the market still hasa bullish sentiment.
At present, the supplier’s inventory is no pressure, and there is no shortage of subsequent increases in expectations. However, the downstream market after this round of market. The demand is expected to be overdrawn in advance, and later buying may gradually weaken. The supply-demand game is rare. It is expected that the market may have further upward prospects in October, but the downward trend in the downstream situation may be difficult to increase.
On the whole, the tight supply of DMF will be eased with the resumptionof the preliminary maintenance equipment and the release of new productioncapacity. In October, downstream demand is still recovering slowly, and thepressure on supply and demand may not be large. It is expected that the marketmay have a high and narrow correction.

Looking for chemical products? Let suppliers reach out to you!
2026-05-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Recommend Reading
-
December’s Coking Coal Market Primarily Exhibits Weak Performance
-
Soaring and Then Plunging Rapidly! The Roller-Coaster Ride of Phenol Comes to an End—What’s Next for the Market?
-
This Week’s Petrocoke Market Prices Rise
-
Cost and Supply Resonance Drives Up Prices—Melamine Market Rises Strongly
-
This week, the soda ash market in China has been operating weakly
-
India Extends Anti-Dumping Duties on Aniline Imports from China for Five More Years
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Ineos Invests £30m to Reduce Emissions at Hull Site by 75%
-
IMM PE Plans to Partially Sell A’pieu Cosmetics Brand
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits